Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | DRD2 | P14416 | 4/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13481957 | 1.00 | MEN1 (0.50) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL13222426 | 0.92 | DRD2 (0.47) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL15031079 | 0.92 | DRD2 (0.47) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL3026936 | 0.91 | DRD2 (0.53) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL3026950 | 0.91 | DRD2 (0.53) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL13481940 | 0.88 | DRD2 (0.49) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL13222400 | 0.84 | DRD2 (0.47) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL13222462 | 0.84 | DRD2 (0.47) | MEN1KMT2ADRD2DRD4DRD3 | |
| Oxalic Acid SCHEMBL3026945 | 0.84 | DRD2 (0.52) | MEN1KMT2ADRD2DRD4DRD3 | |
| SCHEMBL3021540 | 0.83 | DRD2 (0.47) | MEN1KMT2ADRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466296-B2 | Compounds and processes for preparing substituted aminomethyl-2,3,8,9-tetrahydro-7H-1,4-dioxino[2,3-e]indol-8-ones | LIGAND PHARMACEUTICALS (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2046771-B1 | SYNTHESIS OF A COMPOUND WHICH IS SUITABLE AS INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | NEUROGEN CORPORATION (US) | 2010-08-26 | — | — | US | disclosed |
| US-7662979-B2 | cyanation; dopamine autoreceptor agonists and partial agonists at postsynaptic dopamine D2 receptor; for treating dopaminergic disorders such as schizophrenia, schizoaffective disorder, Parkinson's disease, Tourette's syndrome, hyperprolactinemia, and drug addiction | WYETH (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662979-B2 | cyanation; dopamine autoreceptor agonists and partial agonists at postsynaptic dopamine D2 receptor; for treating dopaminergic disorders such as schizophrenia, schizoaffective disorder, Parkinson's disease, Tourette's syndrome, hyperprolactinemia, and drug addiction | WYETH (US) | 2010-02-16 | — | — | US | disclosed |
| CN-101448814-A | Synthesis of a compound which is a suitable intermediate in the synthesis of oxindoledioxane derivatives | WYETH CORP (US) | 2009-06-03 | — | — | CN | disclosed |
| EP-2046771-A2 | SYNTHESIS OF A COMPOUND WHICH IS SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | Wyeth (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | WYETH (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007139998-A2 | SYNTHESIS OF A COMPOUND WHICH IS A SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007139998-A2 | SYNTHESIS OF A COMPOUND WHICH IS A SUITABLE INTERMEDIATE IN THE SYNTHESIS OF OXINDOLEDIOXANE DERIVATIVES | WYETH (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293686-A1 | Oxindoledioxans, synthesis thereof, and intermediates thereto | HTR5A, OPRL1, SLC6A3 | MEN1 4501/4885KMT2A 2032/4885DRD2 7/4885 |
| US-20100217012-A1 | COMPOUNDS AND PROCESSES FOR PREPARING SUBSTITUTED AMINOMETHYL-2,3,8,9-TETRAHYDRO-7H-1,4-DIOXINO[2,3-e]INDOL-8-ONES | MTNR1A, HTR3C, MTNR1B | MEN1 3210/4885KMT2A 870/4885DRD2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.